文献速递脑血管病

结合影像与遗传预测抗凝相关脑出血复发

Combining Imaging and Genetics to Predict Recurrence of Anticoagulation-Associated Intracerebral Hemorrhage.
PubMed 文献 · Stroke · 2020-06-10

该研究联合分析两项纵向队列中口服抗凝治疗相关脑出血(OAT-ICH)幸存者的数据,评估MRI标志物与APOE基因型对ICH复发的预测价值,并开发验证联合分类方案。结果显示皮层表面铁沉积、脑微出血和APOE ε2/ε4独立关联复发,联合模型预测优于临床数据,在验证集中高、中、低危年复发率分别为6.6%、2.5%、0.9%,AUC为0.91。

要点

  • 皮层表面铁沉积、脑微出血和APOE ε2/ε4独立预测OAT-ICH后复发。
  • 联合APOE与MRI的模型预测复发优于临床数据(Harrell C 0.79 vs 0.55)。
  • 验证集高、中、低危年复发率分别为6.6%、2.5%、0.9%,AUC 0.91。

核心结论

  • 联合MRI标志物与APOE基因型可将OAT-ICH后ICH复发风险分层为高、中、低危。
  • 该联合分类方案若经前瞻性研究证实,可能有助于选择OAT-ICH后恢复抗凝的个体。

研究设计与样本

  • 联合分析两项纵向队列:MGH-ICH研究和ERICH研究的纵向部分,对象为OAT-ICH幸存者。
  • 使用分类与回归树分析开发并验证联合APOE-MRI分类方案以预测ICH复发。

主要发现

  • 皮层表面铁沉积、脑微出血和APOE ε2/ε4变异均与OAT-ICH后ICH复发独立相关(均P<0.05)。
  • 联合APOE基因型与MRI数据改善ICH复发预测(Harrell C:0.79 vs 仅临床数据0.55,P=0.033)。
  • 在MGH训练集中,CSS、脑微出血和APOE ε2/ε4将复发可能性分为高、中、低危。
  • 在ERICH验证集中,高、中、低危个体年ICH复发率分别为6.6%、2.5%、0.9%,预测复发总体AUC为0.91。

关键数值与推荐

  • APOE ε2/ε4等位基因、MRI定义的皮层表面铁沉积和脑微出血是复发性ICH最强的风险因素。
  • 联合APOE-MRI分类方案在验证集中预测复发ICH的总体AUC为0.91。
  • 验证集高、中、低危年复发率分别为6.6%、2.5%、0.9%。

临床怎么用

  • 对OAT-ICH幸存者,可结合MRI标志物(皮层表面铁沉积、脑微出血)和APOE基因型评估复发风险。
  • 联合分类方案有助于识别恢复口服抗凝治疗风险最高的患者,辅助临床决策。

局限性

  • 结论基于两项纵向队列的联合分析,需前瞻性研究确认联合分类方案的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: For survivors of oral anticoagulation therapy (OAT)-associated intracerebral hemorrhage (OAT-ICH) who are at high risk for thromboembolism, the benefits of OAT resumption must be weighed against increased risk of recurrent hemorrhagic stroke. The ε2/ε4 alleles of the apolipoprotein E (APOE) gene, MRI-defined cortical superficial siderosis, and cerebral microbleeds are the most potent risk factors for recurrent ICH. We sought to determine whether combining MRI markers and APOE genotype could have clinical impact by identifying ICH survivors in whom the risks of OAT resumption are highest. METHODS: Joint analysis of data from 2 longitudinal cohort studies of OAT-ICH survivors: (1) MGH-ICH study (Massachusetts General Hospital ICH) and (2) longitudinal component of the ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage). We evaluated whether MRI markers and APOE genotype predict ICH recurrence. We then developed and validated a combined APOE-MRI classification scheme to predict ICH recurrence, using Classification and Regression Tree analysis. RESULTS: Cortical superficial siderosis, cerebral microbleed, and APOE ε2/ε4 variants were independently associated with ICH recurrence after OAT-ICH (all P<0.05). Combining APOE genotype and MRI data resulted in improved prediction of ICH recurrence (Harrell C: 0.79 versus 0.55 for clinical data alone, P=0.033). In the MGH (training) data set, CSS, cerebral microbleed, and APOE ε2/ε4 stratified likelihood of ICH recurrence into high-, medium-, and low-risk categories. In the ERICH (validation) data set, yearly ICH recurrence rates for high-, medium-, and low-risk individuals were 6.6%, 2.5%, and 0.9%, respectively, with overall area under the curve of 0.91 for prediction of recurrent ICH. CONCLUSIONS: Combining MRI and APOE genotype stratifies likelihood of ICH recurrence into high, medium, and low risk. If confirmed in prospective studies, this combined APOE-MRI classification scheme may prove useful for selecting individuals for OAT resumption after ICH.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Biffi A, Urday S, Kubiszewski P, et al. Combining Imaging and Genetics to Predict Recurrence of Anticoagulation-Associated Intracerebral Hemorrhage. Stroke. 2020. PMID: 32517581. doi:10.1161/STROKEAHA.120.028310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。